醫渡科技(02158.HK)向3名管理層授出共32.15萬股獎勵股份
醫渡科技(02158.HK)公佈,公司根據首次公開發售後股份獎勵計劃向3名管理層授出合共32.15萬股獎勵股份,其中總裁兼首席財務官楊晶獲授1,250股,首席技術官閆峻獲授11.1萬股,高級副總裁(大數據平臺和解決方案)兼政府事務主管張實獲授約20.9萬股。
待歸屬條件獲達成後,獎勵股份將於2022年4月1日至2025年4月1日之間歸屬。
除其他條款外,每項獎勵均以零代價授出,並給予承授人有條件的權利,以於獎勵股份歸屬時,可獲得相應股份,倘董事會或其代表全權酌情決定,承授人以股份獲得獎勵爲不可行,則可透過出售獎勵股份獲得現金等值物。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.